Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) EPS (Weighted Average and Diluted) (2020 - 2026)

Elicio Therapeutics filings provide 4 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.21 for Q4 2023.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 98.99% to -$0.21 in Q4 2023 year-over-year; TTM through Dec 2023 was -$28.86, a 56.99% increase, with the full-year FY2025 number at -$2.58, up 39.29% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.21 in Q4 2023 for Elicio Therapeutics, up from -$1.27 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.58 in Q4 2021 to a low of -$24.77 in Q1 2023.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$1.34 (2020), compared with a mean of -$6.47.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 130.21% in 2021 and later tumbled 5060.42% in 2023.
  • Elicio Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.92 in 2020, then soared by 130.21% to $0.58 in 2021, then tumbled by 3677.59% to -$20.75 in 2022, then surged by 98.99% to -$0.21 in 2023.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.21 (Q4 2023), -$1.27 (Q3 2023), and -$2.61 (Q2 2023) per Business Quant data.